更新的免疫参考页 – 与疫苗接种相关的肩部损伤 (SIRVA)
Shoulder Injury Related to Vaccine Administration (SIRVA) is a rare but serious complication following suspected inadvertent administration of a vaccine too high in the deltoid or into the shoulder joint. It can cause a local inflammatory response and potential trauma to local structures within the shoulder joint with symptoms lasting for weeks, months or even years.
我们的参考页面最近已更新为详细信息：
- symptoms/features of SIRVA
- impacts and implications
- diagnosis and treatment options
- how to prevent SIRVA
- where to report a case of SIRVA.
要查看完整页面，请点击以下链接：
微血管内皮细胞： Shoulder Injury Related to Vaccine Administration (SIRVA)
更新的免疫参考页：接种 COVID-19 疫苗后的心肌炎和心包炎
MVEC’s myocarditis and pericarditis reference page has been updated following the recent changes to the guidance on myocarditis and pericarditis associated with COVID-19 vaccination.
This update is reflective of ATAGI’s recent advice which has identified that all of the COVID-19 vaccines available within Australia (including non-mRNA COVID-19 vaccines) carry a small increased risk of myocarditis or pericarditis occurring following vaccination.
要查看完整页面，请点击以下链接：
MVEC: Myocarditis and pericarditis following COVID-19 vaccines
Updated immunisation reference page - Pharmacist immunisers
Our pharmacist immuniser reference page has recently been updated to incorporate the expansion of the pharmacist immuniser program allowing accredited pharmacist providers to administer additional vaccines to more people.
Pharmacist immunisers that have completed a recognised ‘Immuniser program of study’, are now authorised to administer the following vaccines in Victoria:
- human papillomavirus (HPV) vaccines to those aged 12 years and older
- pneumococcal vaccines to people aged 50 years and older
- herpes zoster (shingles) vaccine to people aged 50 years and older
- monkeypox vaccines to patients recommended for vaccination aged five years and older.
In addition to this, pharmacist immunisers are now able to administer the diphtheria-tetanus-pertussis (dTpa) vaccine to anyone aged 12 years or older (previously only to those from 15 years of age).
要查看完整页面，请点击以下链接：
新的免疫参考页：体位性心动过速综合征 (POTS) 和免疫
Postural orthostatic tachycardia syndrome (POTS) is a condition that most commonly affects teens and young adults and involves a cluster of symptoms including increased heart rate (tachycardia), dizziness, weakness, vision changes, difficulty concentrating, sleep disturbances or nausea.
No link has been found between vaccination and POTS and a diagnosis of POTS is not a contraindication to receiving vaccinations. In fact, some cases of POTS are thought to occur following an acute infection, some of which are vaccine-preventable.
Vaccination is an important way to stay healthy and protected against disease. Any concerns an individual with POTS has regarding immunisation should be discussed with an individual’s treating healthcare practitioner.
Our new reference page outlines what POTS is and the implications of having POTS on immunisation.
For further information, click on the link below:
Postural orthostatic tachycardia syndrome (POTS) and immunisation
新的免疫参考页：脊髓灰质炎
脊髓灰质炎（脊髓灰质炎）是由 3 种脊髓灰质炎病毒（血清型 1、2 或 3）之一的胃肠道（肠道）感染引起的。脊髓灰质炎病毒是 RNA 肠道病毒，来自 小核糖核酸病毒科 家庭。
大约 70% 的脊髓灰质炎感染没有症状或表现为非特异性发热性疾病。据估计，在所有脊髓灰质炎病例中，弛缓性麻痹的发生率不到 1%。
我们的新参考页面详细介绍了传播途径、流行病学以及通过疫苗接种进行的预防。
要查看完整页面，请点击以下链接：
更新的免疫参考页：疫苗相关增强性疾病 (VAED)
疫苗相关增强性疾病 (VAED) 是一种罕见现象，在这种情况下，通常在未接种疫苗的人身上会出现（通常）更严重的感染临床表现，而在已接种疫苗的人身上会出现这种情况。
MVEC’s reference page on VAED has recently been updated. This resource outlines:
- what VAED is
- mechanisms for enhanced disease
- assessment and evaluation of VAED
要查看完整页面，请点击以下链接：
MVEC: Vaccine-associated enhanced disease (VAED)
疫苗工作 GAVI：过去和现在有关猴痘的五张图表
Despite the first cases of monkeypox infection in humans being reported in the 1970’s, previous outbreaks of disease have been relatively small compared with the international outbreak we are currently experiencing. Human to human transmission has been historically uncommon with cases limited to smaller geographical regions. Current rates of infection, with extensive human to human transmission and wide global spread has led this outbreak to be a very unique scenario.
The following article uses the latest data to explore the current rates of infection across different demographics and regions, the impact of pre-existing medical conditions, as well as vaccine access and severity of disease.
To read the article in full, click on the link below.
疫苗工作 GAVI：过去和现在有关猴痘的五张图表
To view our reference page on monkeypox, click on the link below.
MVEC：猴痘
更新了 MVEC 免疫参考页面：儿童和青少年的 COVID-19 疫苗接种页面
MVEC’s COVID-19 vaccination in children and the adolescent reference page has been updated to include the current recommendations for children under 5 years of age. This resource details:
- Recommended COVID-19 vaccine schedule information for children and adolescents aged ≥ 6 months
- Information on the efficacy and side effects of COVID-19 vaccination in the paediatric population
- Links to current ATAGI COVID-19 vaccine recommendations in the various paediatric and adolescent age groups
要查看完整页面，请点击以下链接：
新的免疫参考页面 – 猴痘
猴痘是一种病毒性人畜共患病（一种从动物传播给人类的感染）。它是由属于 正痘病毒 genus (which also causes the variola virus responsible for smallpox disease and the vaccinia virus, which is used in smallpox vaccines). Since the eradication of smallpox in 1980, monkeypox has become the most important orthopoxvirus affecting humans, however, causes less severe disease than smallpox.
The incubation period of monkeypox is usually 7-14 days, with initial symptoms of monkeypox including fever, headache, backache and muscle aches, fatigue and lymphadenopathy. Historically, smallpox vaccines have been used in the prevention of smallpox infection, however, they are also likely to be effective against monkeypox.
There are two types of smallpox vaccines registered for use in Australia for the prevention of monkeypox, ACAM2000™ and JYNNEOS®.
Our new reference page outlines symptoms, transmission routes, epidemiology, current vaccine recommendations and links to the latest resources.
For further information, click on the link below:
MVEC：猴痘
Updated MVEC immunisation reference page: Travel medicine
Travel medicine focuses on disease prevention and injury risk minimisation for anyone travelling internationally. Recommendations can be based upon the travelling person’s individual circumstances such as the location and purpose of travel, duration and time of year of travel, as well as any underlying medical conditions or other risk factors.
MVEC’s reference page on 旅行药 has recently been updated. This resource outlines:
- where to get travel advice and when to seek advice
- vaccines for travellers
- immunocompromised and pregnant travellers
- advice for visiting friends and relatives (VFR).
要查看完整页面，请点击以下链接：
MVEC: Travel medicine